Press Releases
About Avicanna
Avicanna is a Canadian commercial-stage biopharmaceutical company established in cannabinoid research, development, and evidence-based products for the global consumer, as well as medical and pharmaceutical market segments. In leading global cannabinoid advancements, Avicanna conducts most of its research in Canada at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, located in the MaRS Discovery District. The Company actively collaborates with leading Canadian academic and medical institutions. Avicanna has established an industry-leading scientific platform including advanced R&D and clinical development which has led to the commercialization of over twenty products across four main market segments:
- Medical Cannabis & Wellness Products: RHO Phyto TM
- CBD Derma-Cosmetic Products: Pura H&WTM or Pura EarthTM
- Pharmaceuticals: TruneroxTM
- Cannabis Raw Materials, Seeds, and Bulk Formulations: AureusTM
May 6, 2022
Avicanna Announces Closing of Strategic Private Placement
TORONTO, May 06, 2022 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has closed a strategic non-brokered private placement offering of 4,210,931 units of the Company (the “Units”) at a price of $0.35 per Unit for aggregate gross …
April 5, 2022
Avicanna Expands its Derma-Cosmetics Brand Pura H&W™ into the European Union through a Partnership with Bio-Gate AG
TORONTO, April 05, 2022 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development …
March 31, 2022
Avicanna Announces Filing of Annual Financial Statements for Year Ended December 31, 2021
TORONTO, March 31, 2022 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of …
March 31, 2022
Avicanna Announces Closing of Non-Brokered Private Placement
TORONTO, March 31, 2022 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products …
▪ Avicanna Enters into a Strategic Partnership with Tetra Bio-Pharma – February 10, 2022
▪ Avicanna Provides Q4-2021 Results and Corporate Highlights as well as Fiscal 2022 Guidance – February 02, 2022
▪ Avicanna Announces Closing of Non-Brokered Private Placement of Convertible Debenture Units– January 28, 2022
▪ Avicanna Enters Master Supply Agreement with Chilean Pharmaceutical Pioneer Knop Laboratorios S.A.– January 14, 2022
▪ Avicanna Announces the Appointment of Stephen Kim as Chief Legal Officer & General Counsel– January 10, 2022
▪ Avicanna Announces Changes to its Board of Directors– Jan. 4, 2022
▪ Avicanna Completes First Commercial Export of CBG from Colombia to Czech Republic– Dec. 24, 2021
▪ Avicanna Launches its Clinically Backed CBD Derma-cosmetics Brand, Pura H&W, in the United States in Partnership with Red White and Bloom– Dec. 22, 2021
▪ Avicanna and Harrington Wellness launch re+PLAY™ branded CBD topicals products in Canada– Dec. 20, 2021
▪ Avicanna to Participate in the Lytham Partners Winter 2021 Investor Conference– Dec. 10, 2021
▪ Avicanna Files a Patent to Protect its Advanced Oral Cannabinoid Platform and its Applications for Neurological Diseases– Dec. 06, 2021
▪ Avicanna Enters into an Intellectual Property Licensing and Distribution Agreement with Established Pharmaceutical Company in Argentina– Nov. 30, 2021
▪ Avicanna Expands its Medical Cannabis Brand RHO Phyto into the Caribbean Region with Initial Export to Barbados– Nov. 25, 2021
▪ Avicanna Announces Filing of Interim Financial Statements for the Three-Month Period Ending September 30, 2021, Demonstrating Progressive Commercialization Results– Nov. 12, 2021
▪ Avicanna Announces Resignation of Director– Nov. 11, 2021
▪ Viola Brands Launches Nationwide in Canada through the Medical Cannabis by ShoppersTM online platform– Nov. 9, 2021
▪ Avicanna Inc. to Host Third Quarter 2021 Investor Conference Call on November 12 and Announces Warrant Repricing– Nov. 8, 2021
▪ Avicanna Announces Management Change– Nov. 5, 2021
▪ Avicanna´s subsidiary obtains Good Agricultural and Collection Practices (“GACP”) Certification in Colombia– Nov. 4, 2021
▪ Avicanna Completes Commercial Export of CBD Isolate and CBD Full Spectrum Psychoactive Derivatives from Colombia to Chile– Oct. 22, 2021
▪ Avicanna Closes Non-Brokered Private Placement Raising $3.9 Million and Announces Warrant Repricing– Oct. 19, 2021
▪ Avicanna Completes First Commercial Export of Feminized Cannabis Seeds from Colombia to Peru and Argentina– October 1, 2021
▪ Avicanna Files US Patent Application for a Novel Cannabinoid Formulation in Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy– Sept. 24, 2021
▪ Avicanna Completes Registration and Commercial Export of its Evidence-Based CBD Dermacosmetics Brand, Pura Earth, in Ecuador– Sept. 16, 2021
▪ Avicanna Announces Filing of Interim Financial Statements for Period Ended June 30, 2021 and Provides Corporate Update– Sept. 10, 2021
▪ Avicanna Announces Filing of Annual Financial Statements For Year Ended December 31, 2020– Sept. 03, 2021
▪ Avicanna Completes First Commercial Export of Aureus Branded Full Spectrum Psychoactive CBD Cannabis Extracts to Brazil– Aug 27, 2021
▪ Avicanna Expands Sales of Pura Earth and RHO Phyto Branded Topicals into Alberta’s Retail Channels– Aug 24, 2021
▪ Avicanna Enters Partnership with Heritage Cannabis Holdings Corp. to Commercialize Evidence-Based Topical Products through Heritage’s Medical Cannabis Channels– Aug 11, 2021
▪ Avicanna Announces Partial Revocation of Cease Trade Order and Proposed Financing– August 3, 2021
▪ Avicanna Completes First Commercial Export of Aureus™ Branded THC Active Pharmaceutical Ingredients to Peru– August 3, 2021
▪ Avicanna Completes First Commercial Export of Aureus™ Branded THC Extracts to Austria and Welcomes Colombian Government’s Progressive New Regulation on Cannabis– July 28, 2021
▪ Avicanna Announces Change of Auditor– July 19, 2021
▪ Avicanna and Bio-Gate Complete First Phase of Development on Cannabidiol (CBD) and MicroSilver BG™ Based Skin Care Products for Global Commercialization– June 29, 2021
▪ Avicanna Announces Results of Annual General Meeting and Provides Corporate Update– June 24, 2021
▪ Avicanna Expands The Canadian RHO Phyto Product Offerings With The Addition Of THC-Free High CBD Oral And Sublingual Formulation Across Medical And Adult Use Channels– June 15, 2021
▪ Avicanna Announces Mailing of Management Information Circular and Proposed Board Changes– June 3, 2021
▪ Avicanna’s Evidence-Based and Dermatologist Tested CBD Derma-Cosmetic Brand Pura Earth™ to be Launched in Adult-Use and Medical Channels Across Canada in Q2 2021.– May 26, 2021
▪ Avicanna Makes RHO Phyto™ Medical Cannabis Products Available In Canadian Hospital Pharmacies Through Agreement with Sunnybrook Hospital – May 6, 2021
▪ Avicanna Provides Bi-Weekly Update On Status Of Management Cease Trade Order – April 26, 2021
▪ Avicanna Announces Receipt of Management Cease Trade Order and Provides Bi-Weekly Status Update – April 12, 2021
▪ Avicanna Announces Late Filing of Financial Statements and Application for Management Cease Trade Order – March 29, 2021
▪ Avicanna Closes Non-Brokered Private Placement Raising $5.6 Million – Mar 4, 2021
▪ Avicanna Announces Exercise And Closing Of Over-Allotment Option – Dec 31, 2020
▪ Avicanna Announces Closing of Public Offering of Units – Dec 8, 2020
▪ Avicanna Announces Overnight Marketed Public Offering of Units – Nov 12, 2020
▪ Avicanna Reports Third Quarter 2020 Financial Results and Provides Corporate Update – Nov 12, 2020
▪ Avicanna Closes Non-Brokered Private Placement Raising $2.7 Million – Aug 18, 2020
▪ Avicanna Reports Second Quarter 2020 Financial Results and Provides Corporate Update – Aug 17, 2020
▪ Avicanna Reports First Quarter 2020 Financial Results and Provides Corporate Update – May 25, 2020
▪ Avicanna Closes Non-Brokered Private – Placement with Group of Strategic Investors and Announces Warrant Re-Pricing – April 21, 2020
▪ Avicanna Reports Fourth Quarter 2019 Financial Results and Provides Corporate Update – April 15, 2020
▪ Avicanna Closes First Tranche of Private Placement – January 24, 2020
▪ Avicanna Reports Third Quarter 2019 Financial Results – Nov. 14, 2019
▪ Avicanna Completes its First Exportation of Cannabinoids from Colombia to Canada for Scientific Purposes – Aug 23, 2019
▪ Avicanna Reports Second Quarter 2019 Financial Results – Aug 14, 2019
▪ Avicanna Commences Trading on the TSX Under the Symbol “AVCN” – July 18, 2019
▪ Avicanna Announces TSX Listing Date – July 16, 2019
▪ Avicanna Announces Receipt for Final Prospectus and Conditional Approval for Listing on the TSX – July 10, 2019
▪ Avicanna Closes Oversubscribed $22.1 Million Special Warrant Offering – April 18, 2019
▪ Avicanna Announces Filing of Preliminary Prospectus – January 21, 2019
▪ Avicanna Inc. Acquires 60% Stake in Colombian Medical Marijuana Firm Santa Marta Golden Hemp – August 16, 2018
▪ Avicanna Completes 2nd Equity Financing & Welcomes New Strategic Shareholder – January 29, 2018
▪ Avicanna Closes its First Equity Financing and Announces its Residency at Johnson & Johnson Innovation, JLABS @ Toronto – May 26, 2017
